Scientists Find Treatment To Kill Every Kind Of Cancer Tumor

Jes, Mort, just like an ameri-Scum typical white-man minded individual.
You always “gotta wait” a little while longer with you butt-holes.
So, you wait a while longer, Mort!
And, in the mean time for everyone else who might stumble in here on this worthless article for someone who has CANCER NOW, Mort-with-no-brain,

Cause here is the cure to CANCER and many other things that is here, and very close to you poor unfortunate souls located in the u.s. OF MEDICAL TERROR , right now!
ATTENTION ALL CAPTIVES HELD AGAINST THEIR WILL IN THE u.s. OF MEDICAL TERROR!
I WILL have MERCY ON YOU, and TO SHOW HOW MUCH I HATE YOUR DEA, (and, just call them what they are ……..PIGS ………..that plant evidence, beat and kill pot possessors here in the u.s. of MEDICAL TERROR, all cause they are just ‘doing their jobs’!),
Let me turn you ALL on TO the REAL medicine HERE NOW!
BUT, NOT IN THE u.s. OF MEDICAL TERROR !!!!!!!!!!!!!!!
You see, the rest of the civilized world does not have its medical research community run by A FEDERAL POLICE AGENCY, know as the Drug Enforcement Administration , TRUE LEECH-IN TERRORISTS

The Drug,
Sativex -MANUFACTURED BY A UK COMPANY CALLED
GW Pharmaceuticals
is available to you in Canada right now.
YOU CANNOT HAVE YOUR U.S. DOCTOR “PRESCRIBE” IT, CAUSE IT IS
“LICENSED” BUT NOT APPROVED BY THE FDA AS OF TODAY in the U.S.
You need a Pharmacy in Canada that will accept your order for it and ship it to you in the States.
http://www.gwpharm.com/mechanism-action.aspx
Cannabinoids in General
For a more comprehensive guide to all cannabinoids, their potential therapeutic targets and the mechanisms by which they are thought to operate please visit our R&D mechanism of action section by clicking here.
Sativex
The way in which cannabinoids such as THC exert their effects on the human body is known as their “mechanism of action”. This has recently become clearer with the discovery of two cannabinoid receptors CB1 and CB2 together with that of a chemical called “anandamide”. Anandamide is an endogenous ligand, which literally means that it occurs naturally within the body (endogenous) and is a binding agent or “ligand”. The full name of anandamide is arachidonoyl ethanolamide but it was nicknamed anandamide after the Sanskrit word for bliss “ananda”i. Anandamide has its effect by inhibiting cyclic AMP (part of the cellular energy gerneration process), through G-protein coupling in target cells, which cluster in areas of the central nervous system that mediate painii, memoryiii, and other key functions.
Preliminary tests of pharmacology and behavioural activity support the similarity of anandamide to THCiv. Both anandamide and THC bind weakly to the cannabinoid type one (CB1) receptors, which are found in the brain and are called partial agonistsv,vi.In contrast, cannabidiol (CBD) has little activity at CB1 but greater activity at the cannabinoid type 2 receptors (CB2) that are mostly located in the periphery, in lymphoid tissuesv. CB1 receptor distribution and THC binding affinity at CB1 differ between humans and rodents, which underscores the importance of conducting human clinical trialsvii. Both THC and CBD are neuroprotective antioxidants that have been shown to inhibit NMDA-mediated excitotoxicity under conditions of traumatic head injury, stroke and degenerative brain diseasesviii.
The discovery of the endocannabinoid systemviiihas provided new insights into a neuromodulatory scheme that may provide better explanations of, and treatments for, a wide variety of previously poorly treatable, often painful disordersvi,x.
It has recently been demonstrated that CBD also stimulates vanilloid pain receptors (VR1), inhibits uptake of the anandamide, and weakly inhibits its breakdownxi. These new findings have important implications in elucidating the pain-relieving, anti-inflammatory, and immunodulatory effects of CBD.
The combination of THC, CBD and essential oils in cannabis-based medicinal extracts may produce a therapeutic preparation whose benefits are greater than the sum of its partsxii.
http://projectcbd.org/
ABOUT CANNABIDIOL (and us)
Cannabidiol —CBD— is a compound in Cannabis that has medical effects but does not make people feel “stoned” and actually counters some of the effects of THC. After decades in which only high-THC Cannabis was available, CBD-rich strains are now being grown by and for medical users.
The reduced psychoactivity of CBD-rich Cannabis may make it an appealing treatment option for patients seeking anti-inflammatory, anti-pain, anti-anxiety and/or anti-spasm effects without disconcerting euphoria or lethargy.
Scientific and clinical studies indicate that CBD could be effective in easing symptoms of a wide range of difficult-to-control conditions, including: rheumatoid arthritis, diabetes, alcoholism, PTSD, epilepsy, antibiotic-resistant infections and neurological disorders. CBD has demonstrated neuroprotective effects, and its anti-cancer potential is currently being explored at several academic research centers in the U.S. and other countries.
The Story to Date
In the spring of 1998, the British government licensed a company called GW Pharmaceuticals to grow Cannabis and develop a precisely consistent plant extract for use in clinical trials. GW’s co-founder Geoffrey Guy, MD, was convinced —and had convinced the Home Office— that by using CBD-rich plants, GW could produce a Cannabis-based medicine with little or no psychoactive effect. That summer Guy described his approach at a meetingof the International Cannabinoid Research Society. In addition to countering the psychoactivity of THC, Guy said, CBD conferred benefits of its own. Queen Victoria had used CBD-rich Cannabis for menstrual cramps. Indeed, animal studies suggest that CBD lessened anxiety and reduced the severity and frequency of seizures.
It was assumed that generations of breeding for maximum THC had reduced CBD in California cannabis to trace levels. GW had gotten its CBD-rich strains by acquiring the genetic library of HortaPharm, a Dutch seed company run by American ex-pat naturalists, David Watson and Robert Clarke. Tod Mikuriya, MD, founder of the Society of Cannabis Clinicians, expressed hope that “our Burbanks in the hills” would have preserved or could develop CBD-rich strains if and when an analytic test lab began serving the medical Cannabis industry.
As the years went by, more and more promising studies involving CBD were described at meetings of the ICRS, the International Association for Cannabinoid Medicine, and Patients Out of Time. California doctors kept abreast of the research and O’Shaughnessy’s reported on it, but we were merely observers, not participants —until the fall of 2008, when Oakland’s Steep Hill Laboratory began testing samples provided by Harborside Health Center.
Approximately one in 750 samples of Cannabis being grown for medical use is turning out to be CBD-rich. (For data collection purposes, “CBD-rich” has been defined as 4% or more by dry weight.) Doctors and patients now have a unique opportunity to evaluate its effects.
Read about recent developments in our CBDiary, a catch-all column for news generated by patients, doctors, dispensaries, growers, plant breeders, pharmacologists, the industry, the government —all the players— as the CBD story unfolds. Send your items here.
Cannabis Compound Found Superior To Drugs For Alzheimer’s
Sayer Ji, Contributor
Activist Post
Could the active ingredient in marijuana, responsible for its characteristic “high,” help turn the tide against the accelerating Alzheimer’s epidemic?
A remarkable study published in the journal Molecular Pharmacology in 2006, found that this long-vilified plant contains a compound with not one, but two therapeutic properties ideal for addressing both the surface symptom (memory problems) and root cause (brain plaque) of Alzheimer’s disease.[i] This is an ironic finding, considering that the prevailing stereotype is that using marijuana “fries” the brain, leading to debilitating memory issues.
Researchers discovered that the psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), both “competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid β-peptide (Aβ) aggregation.”
On the first account, THC’s ability to inhibit the AChE enzyme, is not unlike the mechanism of action behind most Alzheimer’s drugs on the market today. Drugs like donepezil (trade name Aricept), for instance, by targeting and inhibiting the brain enzyme acetylcholinesterase (AChE), result in an increase in brain levels of this neurotransmitter, which in turn, results in symptom reduction, i.e. improved memory. Donepezil, however, is riddled with controversy due its well-known association with seizures, which likely reflects its intrinsic neurotoxicity. It is, in fact, a chemical in the same general chemical class as venom, insecticides and chemical war agents, such as nerve gas.
On the second account, THC’s ability to prevent the acetylcholinesterase-associated amyloid β-peptide (Aβ) aggregation, i.e. brain plaque, indicates that it may, as the researchers noted, “directly impact Alzheimer’s disease pathology.” In fact, they found “Compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.”
What is so encouraging about this research, and which the researchers described as “noteworthy,” is the following:
THC is a considerably more effective inhibitor of AChE-induced Aβ deposition than the approved drugs for Alzheimer’s disease treatment, donepezil and tacrine, which reduced Aβ aggregation by only 22% and 7%, respectively, at twice the concentration used in our studies.7 Therefore, AChE inhibitors such as THC and its analogues may provide an improved therapeutic for Alzheimer’s disease, augmenting acetylcholine levels by preventing neurotransmitter degradation and reducing Aβ aggregation, thereby simultaneously treating both the symptoms and progression of Alzheimer’s disease.
THC, of course, is only one of a wide range of cannabinoids in the plant marijuana. Not only is there already plentiful information on the neuroprotective properties of marijuana compounds, but there is also a sizeable body of clinical and/or biomedical research indicating the medicinal value of this plant in over 150 health conditions. To view this research visit our Medical Marijuana Research page.
Notes:
[i] Lisa M Eubanks, Claude J Rogers, Albert E Beuscher, George F Koob, Arthur J Olson, Tobin J Dickerson, Kim D Janda . A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm. 2006 Nov-Dec;3(6):773-7. PMID: 17140265
You can support this information by voting on Reddit HERE
This article first appeared at GreenMedInfo. Please visit to access their vast database of articles and the latest information in natural health.
AND, GOOD LUCK WITH THE ameri-NAZI “ALPHABET-SOUP PIG AGENCIES YOU NEED TO DESTROY.
AND SOON
They sure as hell love killing you, don’t they?